Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared on X:
“Ponatinib–Blinatumomab in Adult Ph-Positive ALL
Definitely a step in the right direction for frontline Ph+ ALL.
The major caveat is the comparator: imatinib is no longer our preferred frontline TKI. A contemporary comparator using a more potent TKI would have made the results much more informative for current practice.”
You can also read: Optimizing Asparaginase and Blinatumomab in Frontline Acute Lymphoblastic Leukemia – Resonance
